Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. cut its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL) by 48.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 231,825 shares of the company’s stock after selling 221,883 shares during the quarter. Rockefeller Capital Management L.P. owned about 0.50% of Omnicell worth $10,316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OMCL. Vanguard Group Inc. boosted its position in shares of Omnicell by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 5,562,165 shares of the company’s stock worth $247,628,000 after buying an additional 28,573 shares during the period. Victory Capital Management Inc. boosted its holdings in Omnicell by 32.9% during the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company’s stock valued at $67,951,000 after acquiring an additional 377,883 shares during the period. Sumitomo Mitsui Trust Group Inc. grew its position in Omnicell by 93.3% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after acquiring an additional 699,925 shares in the last quarter. Geode Capital Management LLC increased its stake in Omnicell by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after purchasing an additional 2,877 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Omnicell by 3.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 616,153 shares of the company’s stock worth $27,431,000 after purchasing an additional 21,157 shares in the last quarter. 97.70% of the stock is owned by institutional investors and hedge funds.

Omnicell Stock Down 1.3 %

Shares of NASDAQ OMCL opened at $30.95 on Thursday. The business has a 50-day moving average of $35.74 and a two-hundred day moving average of $41.45. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of 114.63, a price-to-earnings-growth ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. On average, analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on OMCL. Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. JPMorgan Chase & Co. cut their price objective on Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research report on Thursday, March 20th. Bank of America decreased their target price on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a report on Monday, January 6th. StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a report on Tuesday. Finally, Benchmark reiterated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $51.00.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.